Broadfin Capital’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Broadfin Capital’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-52,432	Closed	-$3.22M	–	66
2018 Q1	$3.22M	Buy	52,432 +7,977	+18%	+$700K	0.5%	44
2017 Q4	$5.6M	Sell	44,455 -545	-1%	-$69.8K	0.92%	28
2017 Q3	$6.16M	Buy	+45,000	New	+$6.02M	0.91%	27
2015 Q4	–	Sell	-8,002	Closed	-$1.19M	–	100
2015 Q3	$1.19M	Buy	+8,002	New	+$5.87M	0.07%	89
2014 Q4	–	Sell	-47,962	Closed	-$19.1M	–	82
2014 Q3	$19.1M	Sell	47,962 -57,825	-55%	-$15.5M	2.01%	14
2014 Q2	$28.5M	Buy	105,787 +5,381	+5%	+$1.15M	2.78%	10
2014 Q1	$21.9M	Sell	100,406 -9,260	-8%	-$2.58M	2.12%	12
2013 Q4	$29.7M	Buy	109,666 +20,000	+22%	+$4.77M	3.91%	8
2013 Q3	$20.4M	Buy	89,666 +18,250	+26%	+$3.19M	3.62%	9
2013 Q2	$10M	Buy	+71,416	New	+$11.3M	1.96%	18

Other funds holding TTPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Broadfin Capital's TTPH Position: Q2 2018 in Review

Broadfin Capital sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q2 2018, closing a stake of 52,432 shares — an estimated $3.22M sold.

Broadfin Capital first reported a position in TTPH in Q2 2013 and held it in 10 quarters. The position peaked at $29.7M in Q4 2013. 90 funds tracked by Wall St. Rank hold TTPH as of Q2 2018.

Broadfin Capital reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Broadfin Capital sold 52,432 Tetraphase Pharmaceuticals, Inc. shares in Q2 2018, an estimated $3.22M.
Broadfin Capital first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2013 and held it in 10 quarters.
Broadfin Capital's Tetraphase Pharmaceuticals, Inc. position peaked at $29.7M in Q4 2013.
90 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q2 2018.

Based on Broadfin Capital's 13F filing for Q2 2018, filed 14 Aug 2018.